HS-20089 + adebrelimab + cisplatin + carboplatin

**HS-20089 + adebrelimab + cisplatin + carboplatin** is a combination regimen under investigation for advanced solid tumors, including ovarian and endometrial cancer[5]. - **HS-20089** is a B7-H4-targeted antibody-drug conjugate (ADC): a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload (drug-antibody ratio ~6), administered intravenously[1][3][5][7]. - **Adebrelimab** is a human anti-PD-L1 monoclonal antibody that blocks the interaction of PD-L1 with PD-1, enhancing anti-tumor immune responses (mechanism analogous to other anti-PD-L1 checkpoint inhibitors). - **Cisplatin** and **carboplatin** are platinum-based chemotherapeutics that crosslink DNA leading to cell death (by inhibiting DNA replication and transcription); they have non-overlapping toxicity profiles and can be used together for dose intensification[2][4][6]. This regimen is under phase I clinical investigation for safety, tolerability, PK, and efficacy in subjects with advanced solid tumors, with individualized dose escalation cohorts for combination therapy.